Opus Genetics, Inc. (IRD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Company Overview - Opus Genetics is a clinical stage biopharmaceutical company focused on developing gene therapies for inherited retinal diseases [2] - The company trades under the ticker symbol IRD and has a multi-asset pipeline [2] Pipeline and Milestones - Opus Genetics has near-term data readouts and multiple milestones expected in 2026 [2]